Inve India ▾

Quick Heal Technologies share price & results

Quick Heal Technologies Limited· Information Technology

Results to
Jun 2026
Latest analysed call
Q4 FY26
Ownership as of
Sept 2026

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue45.0 ₹ crore−21.4% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin-38.7 %−21.8 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit-5.1 ₹ crore—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equity-2.44 %−4.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin2.30 %+15.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-6.64 %−2.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

0 of 3 judged targets kept · 4 open · verdicts reflect calls analysed to Q4 FY26.

Quick Heal Technologies Limited management guidance track record on Inve: 7 targets tracked across analysed earnings calls (0 achieved, 3 missed, 4 open).

TargetOriginal wordingSaidLatest callVerdict
Total Addressable Market (SOM)INR 4,000 crores over the 2 to 3 years
Call transcript, Q2 FY26 · 16 Oct 2025
Q2 FY26Q4 FY26:The specific INR 4,000 crore TAM figure was not reiterated. However, management reinforced the underlying strategy by guiding for the enterprise vertical to reach 80-90% of revenue in 2-3 years, which aligns with the previous TAM breakdown.
Call transcript, Q4 FY26 · 22 May 2026
Ghosted
Receivables / Collection IssuesConfident that in the coming quarters, we will come out of this situation.
Call transcript, Q2 FY26 · 16 Oct 2025
Q2 FY26Q4 FY26:Management reported that overdues, after worsening mid-year to INR 176 crores, have now improved significantly to INR 138 crores due to tightened credit controls, showing progress on the commitment.
Call transcript, Q4 FY26 · 22 May 2026
On Track

Source: Inve Guidance Tracker for Quick Heal Technologies Limited · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Quick Heal Technologies Limited's 7 targets were missed. See which ones, and which are quietly gone. The 2 above are the free sample; 5 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹138.16 +2.65% · +₹3.57

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −57.4% 1Y

₹150₹200₹250₹300Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q4 FY26 — 22 May 2026

1Y: ₹324.5 on 24 Oct 2025 → ₹138.16. High ₹326.5 (13 Nov 2025), low ₹125.53 (30 Mar 2026).

Previous close
₹134.59
Market cap
₹750 Cr
52-week range
₹125.53 – ₹326.5
One year
−57.44%
Return on equity (TTM to Jun 2026)
-2.44%

Overview

Symbol
NSE:QUICKHEAL
Exchange
NSE
Currency
INR

How the price took the results

close before → close after

Q4 FY26
−7.1%
22 May

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Quick Heal Technologies Limited

Free account: one company. Everything above stays public.

Write why you follow Quick Heal Technologies Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds